tetano
Editor, Senior Moderator
Vaccine. 2015 Oct 15. pii: S0264-410X(15)01429-2. doi: 10.1016/j.vaccine.2015.10.014. [Epub ahead of print]
[h=1]Report on the second WHO integrated meeting on development and clinical trials of influenza vaccines that induce broadly protective and long-lasting immune responses: Geneva, Switzerland, 5-7 May 2014.[/h] Cox NJ[SUP]1[/SUP], Hickling J[SUP]2[/SUP], Jones R[SUP]2[/SUP], Rimmelzwaan GF[SUP]3[/SUP], Lambert LC[SUP]4[/SUP], Boslego J[SUP]5[/SUP], Rudenko L[SUP]6[/SUP], Yeolekar L[SUP]7[/SUP], Robertson J[SUP]8[/SUP], Hombach J[SUP]9[/SUP], Ortiz JR[SUP]9[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] On 5-7 May 2014, the World Health Organization (WHO) convened the second integrated meeting on "influenza vaccines that induce broadly protective and long-lasting immune responses". Around 100 invited experts from academia, the vaccine industry, research and development funders, and regulatory and public health agencies attended the meeting. Areas covered included mechanisms of protection in natural influenza-virus infection and vaccine-induced immunity, new approaches to influenza-vaccine design and production, and novel routes of vaccine administration. A timely focus was on how this knowledge could be applied to both seasonal influenza and emerging viruses with pandemic potential such as influenza A (H7N9), currently circulating in China. Special attention was given to the development of possible universal influenza vaccines, given that the Global Vaccine Action Plan calls for at least one licensed universal influenza vaccine by 2020. This report highlights some of the topics discussed and provides an update on studies published since the report of the previous meeting.
Copyright ? 2015. Published by Elsevier Ltd.. All rights reserved.
[h=4]KEYWORDS:[/h] H7N9 vaccine; Influenza; Pandemic influenza vaccine; Seasonal influenza vaccine; Universal influenza vaccine; Vaccine
PMID: 26478203 [PubMed - as supplied by publisher]
[h=1]Report on the second WHO integrated meeting on development and clinical trials of influenza vaccines that induce broadly protective and long-lasting immune responses: Geneva, Switzerland, 5-7 May 2014.[/h] Cox NJ[SUP]1[/SUP], Hickling J[SUP]2[/SUP], Jones R[SUP]2[/SUP], Rimmelzwaan GF[SUP]3[/SUP], Lambert LC[SUP]4[/SUP], Boslego J[SUP]5[/SUP], Rudenko L[SUP]6[/SUP], Yeolekar L[SUP]7[/SUP], Robertson J[SUP]8[/SUP], Hombach J[SUP]9[/SUP], Ortiz JR[SUP]9[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] On 5-7 May 2014, the World Health Organization (WHO) convened the second integrated meeting on "influenza vaccines that induce broadly protective and long-lasting immune responses". Around 100 invited experts from academia, the vaccine industry, research and development funders, and regulatory and public health agencies attended the meeting. Areas covered included mechanisms of protection in natural influenza-virus infection and vaccine-induced immunity, new approaches to influenza-vaccine design and production, and novel routes of vaccine administration. A timely focus was on how this knowledge could be applied to both seasonal influenza and emerging viruses with pandemic potential such as influenza A (H7N9), currently circulating in China. Special attention was given to the development of possible universal influenza vaccines, given that the Global Vaccine Action Plan calls for at least one licensed universal influenza vaccine by 2020. This report highlights some of the topics discussed and provides an update on studies published since the report of the previous meeting.
Copyright ? 2015. Published by Elsevier Ltd.. All rights reserved.
[h=4]KEYWORDS:[/h] H7N9 vaccine; Influenza; Pandemic influenza vaccine; Seasonal influenza vaccine; Universal influenza vaccine; Vaccine
PMID: 26478203 [PubMed - as supplied by publisher]